Biomarin Pharmaceutical Stock Price Patterns
| BMRN Stock | USD 57.81 0.32 0.55% |
Momentum 49
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 1.243 | EPS Estimate Next Quarter 0.9872 | EPS Estimate Current Year 3.3616 | EPS Estimate Next Year 5.2217 | Wall Street Target Price 89.087 |
Using Biomarin Pharmaceutical hype-based prediction, you can estimate the value of Biomarin Pharmaceutical from the perspective of Biomarin Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Biomarin Pharmaceutical using Biomarin Pharmaceutical's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Biomarin using crowd psychology based on the activity and movement of Biomarin Pharmaceutical's stock price.
Biomarin Pharmaceutical Short Interest
An investor who is long Biomarin Pharmaceutical may also wish to track short interest. As short interest increases, investors should be becoming more worried about Biomarin Pharmaceutical and may potentially protect profits, hedge Biomarin Pharmaceutical with its derivative instruments, or be ready for some potential downside.
200 Day MA 56.6114 | Short Percent 0.0493 | Short Ratio 2.51 | Shares Short Prior Month 8.1 M | 50 Day MA 56.5886 |
Biomarin Pharmaceutical Hype to Price Pattern
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Biomarin Pharmaceutical's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Biomarin Pharmaceutical.
Biomarin Pharmaceutical Implied Volatility | 0.49 |
Biomarin Pharmaceutical's implied volatility exposes the market's sentiment of Biomarin Pharmaceutical stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biomarin Pharmaceutical's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biomarin Pharmaceutical stock will not fluctuate a lot when Biomarin Pharmaceutical's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Biomarin Pharmaceutical to buy its stock at a price that has no basis in reality. In that case, they are not buying Biomarin because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Biomarin Pharmaceutical after-hype prediction price | USD 58.19 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Biomarin contract
Based on the Rule 16, the options market is currently suggesting that Biomarin Pharmaceutical will have an average daily up or down price movement of about 0.0306% per day over the life of the 2026-05-15 option contract. With Biomarin Pharmaceutical trading at USD 57.81, that is roughly USD 0.0177 . If you think that the market is fully incorporating Biomarin Pharmaceutical's daily price movement you should consider acquiring Biomarin Pharmaceutical options at the current volatility level of 0.49%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Biomarin Pharmaceutical Basic Forecasting Models to cross-verify your projections. Biomarin Pharmaceutical After-Hype Price Density Analysis
As far as predicting the price of Biomarin Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Biomarin Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Biomarin Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Biomarin Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Biomarin Pharmaceutical's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Biomarin Pharmaceutical's historical news coverage. Biomarin Pharmaceutical's after-hype downside and upside margins for the prediction period are 55.42 and 60.96, respectively. We have considered Biomarin Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Biomarin Pharmaceutical is very steady at this time. Analysis and calculation of next after-hype price of Biomarin Pharmaceutical is based on 3 months time horizon.
Biomarin Pharmaceutical Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Biomarin Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.13 | 2.77 | 0.06 | 0.16 | 10 Events / Month | 7 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
57.81 | 58.19 | 0.10 |
|
Biomarin Pharmaceutical Hype Timeline
Biomarin Pharmaceutical is currently traded for 57.81. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of -0.16. Biomarin is projected to increase in value after the next headline, with the price projected to jump to 58.19 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.1%, whereas the daily expected return is currently at 0.13%. The volatility of related hype on Biomarin Pharmaceutical is about 225.39%, with the expected price after the next announcement by competition of 57.65. The company reported the previous year's revenue of 3.09 B. Net Income was 426.86 M with profit before overhead, payroll, taxes, and interest of 2.52 B. Given the investment horizon of 90 days the next projected press release will be in about 10 days. Check out Biomarin Pharmaceutical Basic Forecasting Models to cross-verify your projections.Biomarin Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Biomarin Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Biomarin Pharmaceutical's future price movements. Getting to know how Biomarin Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Biomarin Pharmaceutical may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EXEL | Exelixis | (0.06) | 11 per month | 1.67 | 0.07 | 4.06 | (2.93) | 11.45 | |
| MRNA | Moderna | (0.59) | 9 per month | 3.71 | 0.16 | 9.21 | (6.55) | 23.11 | |
| RVMD | Revolution Medicines | 0.44 | 10 per month | 3.00 | 0.16 | 4.56 | (2.52) | 45.50 | |
| TECH | Bio Techne Corp | 1.64 | 7 per month | 1.71 | 0.03 | 3.76 | (2.93) | 10.34 | |
| HALO | Halozyme Therapeutics | 0.15 | 28 per month | 1.65 | 0.12 | 3.72 | (2.83) | 9.83 | |
| MDGL | Madrigal Pharmaceuticals | (17.67) | 10 per month | 2.04 | 0.06 | 7.29 | (3.26) | 16.78 | |
| RNA | Avidity Biosciences | 0.09 | 9 per month | 0.00 | (0.09) | 0.38 | (0.29) | 1.75 | |
| BBIO | BridgeBio Pharma | 2.64 | 9 per month | 3.08 | 0.03 | 4.65 | (3.46) | 21.24 | |
| ALGN | Align Technology | (1.09) | 9 per month | 1.24 | 0.17 | 4.70 | (2.54) | 11.36 | |
| QGEN | Qiagen NV | 2.16 | 10 per month | 1.11 | 0.07 | 2.86 | (2.52) | 19.34 |
Biomarin Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Biomarin price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Biomarin using various technical indicators. When you analyze Biomarin charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Biomarin Pharmaceutical Predictive Indicators
The successful prediction of Biomarin Pharmaceutical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biomarin Pharmaceutical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biomarin Pharmaceutical based on analysis of Biomarin Pharmaceutical hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Biomarin Pharmaceutical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biomarin Pharmaceutical's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 95.61 | 84.48 | 97.15 | 99.68 | PTB Ratio | 3.66 | 2.21 | 1.99 | 3.91 |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.63 | EDIT | Editas Medicine | PairCorr |
| 0.63 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.58 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.51 | QSI | QuantumSi | PairCorr |
| 0.46 | ABP | Abpro Holdings | PairCorr |
| 0.46 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Biomarin Pharmaceutical Basic Forecasting Models to cross-verify your projections. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Biomarin diversify its offerings? Factors like these will boost the valuation of Biomarin Pharmaceutical. Projected growth potential of Biomarin fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomarin Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.243 | Earnings Share 2.69 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value - what Biomarin Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.